Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ALIM | US
-0.01
-0.18%
Healthcare
Drug Manufacturers - Major
30/06/2024
30/08/2024
5.53
5.56
5.57
5.53
Alimera Sciences Inc. a pharmaceutical company engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States internationally and Operating Cost segments. It offers ILUVIEN an intravitreal implant for the treatment of diabetic macular edema (DME) which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices pharmacies clinics and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences Inc. was incorporated in 2003 and is headquartered in Alpharetta Georgia.
View LessStrong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
4.3%1 month
3.7%3 months
152.9%6 months
115.2%5.27
131.58
7.75
1.86
0.48
31.62
3.61
-
14.78M
300.74M
300.74M
-
7.86
-
54.00
-34.57
2.49
3.51
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.09
Range1M
0.09
Range3M
2.88
Rel. volume
3.67
Price X volume
6.10M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Rockwell Medical Inc | RMTI | Drug Manufacturers - Major | 2.86 | 88.75M | -2.39% | n/a | 61.18% |
ProPhase Labs Inc | PRPH | Drug Manufacturers - Major | 2.69 | 51.32M | 12.08% | n/a | 60.84% |
NanoViricides Inc | NNVC | Drug Manufacturers - Major | 1.95 | 23.04M | 3.72% | n/a | 0.00% |
TherapeuticsMD Inc | TXMD | Drug Manufacturers - Major | 1.885 | 21.74M | 0.27% | n/a | 27.44% |
China Pharma Holdings Inc | CPHI | Drug Manufacturers - Major | 0.2019 | 3.47M | -3.40% | n/a | 54.76% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Marine Products Corporation | MPX | Recreational Vehicles | 9.4 | 326.35M | 0.00% | 12.70 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 18.53 | 314.66M | -0.70% | 36.33 | 26.79% |
Wallbox N.V. | WBX | Electronic Components | 1.37 | 288.62M | -1.44% | n/a | 164.45% |
MicroVision Inc | MVIS | Electronic Components | 0.9482 | 201.73M | 4.75% | n/a | 17.85% |
STHO | STHO | Real Estate Services | 13.4 | 178.48M | -1.40% | n/a | 0.00% |
Douglas Elliman Inc. | DOUG | Real Estate Services | 1.78 | 163.46M | -2.20% | n/a | 62.82% |
Syntec Optics Holdings Inc. | OPTX | Electronic Components | 1.43 | 115.66M | 1.27% | n/a | 0.00% |
Neonode Inc | NEON | Electronic Components | 7.25 | 112.13M | 3.87% | n/a | 0.17% |
Babcock & Wilcox Enterprises Inc | BW | Electronic Components | 1.18 | 108.79M | -3.28% | n/a | -267.72% |
OPAD | OPAD | Real Estate Services | 3.89 | 106.41M | -2.26% | n/a | 406.11% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 31.62 | - | Expensive |
Ent. to Revenue | 3.61 | - | Cheaper |
PE Ratio | 5.27 | 38.66 | Cheaper |
Price to Book | 7.75 | 10.88 | Cheaper |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 152.89 | - | Riskier |
Debt to Equity | 1.86 | 1.63 | Par |
Debt to Assets | 0.48 | 0.32 | Expensive |
Market Cap | 300.74M | - | Emerging |